Pharmacist's Letter Canada

Article: how to manage osteoporosis when patients don't get enough benefit from a bisphosphonate October 2013

Commentary: Managing Suboptimal Response to Bisphosphonates October 2013

PL Voices: Managing Osteoporosis When a Bisphosphonate Isn’t Enough October 2013

Article: STOPPING bisphosphonates (alendronate, etc) after 3 to 5 years in patients at low fracture risk July 2013

Commentary: Optimal Duration of Bisphosphonate Therapy July 2013

PL Voices: Questions About Stopping Bisphosphonates July 2013

Patient Education: What I Need to Know About My Bisphosphonate July 2013

Article: more negative press about calcium supplements April 2013

Commentary: Calcium and Cardiovascular Risk April 2013

Article: rev up promotion of Uloric (febuxostat) for managing gout December 2012

Guideline: 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia December 2012

PL Voices: Strategies for Managing Gout December 2012

Guideline: 2012 American College of Rheumatology Guidelines for Management of Gout. Part 2: Therapy and Antiinflammatory Prophylaxis of Acute Gouty Arthritis December 2012

Article: whether inhaled corticosteroids inhibit growth in kids or increase fracture risk in seniors October 2012

Commentary: The Effects of Inhaled Corticosteroids on Growth and Fractures October 2012

Resources